{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T16:39:45Z","timestamp":1751906385775,"version":"3.37.3"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2014,2,1]],"date-time":"2014-02-01T00:00:00Z","timestamp":1391212800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ecco-jccjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Crohn's and Colitis"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1016\/j.crohns.2013.07.004","type":"journal-article","created":{"date-parts":[[2013,8,7]],"date-time":"2013-08-07T04:16:50Z","timestamp":1375849010000},"page":"120-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients"],"prefix":"10.1093","volume":"8","author":[{"given":"D.R.","family":"Wong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Pierik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Seinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.","family":"van Bodegraven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.P.L.","family":"Gilissen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Bus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.A.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.A.M.","family":"Masclee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Neef","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.G.J.B.","family":"Engels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.M.","family":"Hooymans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"10.1016\/j.crohns.2013.07.004_bb0005","first-page":"CD000545","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease","author":"Prefontaine","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.crohns.2013.07.004_bb0010","first-page":"CD000067","article-title":"Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease","author":"Prefontaine","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.crohns.2013.07.004_bb0015","first-page":"CD000478","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.crohns.2013.07.004_bb0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2174\/138161210790112773","article-title":"Pharmacogenetics of thiopurines in inflammatory bowel disease","volume":"16","author":"Derijks","year":"2010","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.crohns.2013.07.004_bb0025","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1053\/j.gastro.2006.01.046","article-title":"Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis","volume":"130","author":"Osterman","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.07.004_bb0030","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.crohns.2011.12.003","article-title":"Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy","volume":"6","author":"Gilissen","year":"2012","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2013.07.004_bb0035","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/gut.39.3.401","article-title":"6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity","volume":"39","author":"Cuffari","year":"1996","journal-title":"Gut"},{"key":"10.1016\/j.crohns.2013.07.004_bb0040","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0016-5085(00)70140-5","article-title":"Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease","volume":"118","author":"Dubinsky","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.crohns.2013.07.004_bb0045","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1002\/ibd.21458","article-title":"Clinical usefulness of therapeutic drug monitoring in patients with inadequately controlled inflammatory bowel disease","volume":"17","author":"Haines","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.07.004_bb0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1365-2036.2011.04905.x","article-title":"Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease","volume":"35","author":"Chouchana","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.07.004_bb0055","first-page":"106","author":"D'Haens","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.07.004_bb0060","first-page":"A1899","article-title":"Richtlijn \u2018Diagnostiek en behandeling van inflammatoire darmziekten bij volwassenen\u2019 I. Diagnostiek en behandeling","volume":"154","author":"Van Bodegraven","year":"2010","journal-title":"Ned Tijdschr Geneeskd"},{"key":"10.1016\/j.crohns.2013.07.004_bb0065","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.crohns.2009.12.002","article-title":"The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management","volume":"4","author":"Dignass","year":"2010","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.crohns.2013.07.004_bb0070","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","article-title":"Infliximab, azathioprine, or combination therapy for Crohn's disease","volume":"362","author":"Colombel","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.crohns.2013.07.004_bb0075","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1365-2036.2003.01778.x","article-title":"Drug interaction between infliximab and azathioprine in patients with Crohn's disease","volume":"18","author":"Roblin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.07.004_bb0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00007691-200406000-00016","article-title":"Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease; implications for therapy","volume":"26","author":"Derijks","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.crohns.2013.07.004_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1572-0241.2007.01511.x","article-title":"Dose-dependent influence of 5-aminosalicylates on thiopurine metabolism","volume":"102","author":"De Boer","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.crohns.2013.07.004_bb0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2125.1994.tb04314.x","article-title":"Thiopurine methyltransferase activity in a French population: HPLC assay conditions and effects of drugs and inhibitors","volume":"38","author":"Jacques-Aigrain","year":"1994","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.crohns.2013.07.004_bb0095","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/15257770600894253","article-title":"Determination of ITPase activity in erythrocyte lysates obtained for determination of TPMT activity","volume":"25","author":"Bierau","year":"2006","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.crohns.2013.07.004_bb0100","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0009-8981(02)00243-7","article-title":"Simple non-radiochemical HPLC-linked method for screening for purine metabolism disorders using dried blood spot","volume":"324","author":"Jacomelli","year":"2002","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.crohns.2013.07.004_bb0105","series-title":"Presented at the European Crohn's and Colitis Organization (ECCO) Congress, Stockholm","article-title":"Infliximab, azathioprine, or infliximab+azathioprine for treatment of moderate to severe ulcerative colitis: The UC SUCCESS trial. Oral presentation (Abstract OP 13)","author":"Panaccione","year":"2011"},{"key":"10.1016\/j.crohns.2013.07.004_bb0110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/S0140-6736(08)60304-9","article-title":"Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial","volume":"371","author":"D'Haens","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.crohns.2013.07.004_bb0115","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1111\/apt.12076","article-title":"Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?","volume":"36","author":"Reenaers","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.07.004_bb0120","doi-asserted-by":"crossref","first-page":"E54","DOI":"10.1002\/ibd.22998","article-title":"Infliximab treatment induces levels of the active azathioprine metabolite 6-TGTP in Crohn's disease","volume":"19","author":"Teichgr\u00e4ber","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.crohns.2013.07.004_bb0125","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S1542-3565(05)00697-X","article-title":"6-Thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease","volume":"3","author":"Neurath","year":"2005","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.crohns.2013.07.004_bb0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/00855920310002726","article-title":"Safety of thiopurines in the treatment of inflammatory bowel disease","volume":"239","author":"de Jong","year":"2003","journal-title":"Scand J Gastroenterol Suppl"},{"author":"EMA","key":"10.1016\/j.crohns.2013.07.004_bb0135"},{"key":"10.1016\/j.crohns.2013.07.004_bb0140","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2036.2005.02630.x","article-title":"The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients","volume":"22","author":"Gilissen","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.crohns.2013.07.004_bb0145","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/j.1476-5381.2010.00731.x","article-title":"Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy","volume":"160","author":"de Graaf","year":"2010","journal-title":"Br J Pharmacol"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994613002420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1873994613002420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/8\/2\/120\/1616675\/8-2-120.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,23]],"date-time":"2017-08-23T01:16:08Z","timestamp":1503450968000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-lookup\/doi\/10.1016\/j.crohns.2013.07.004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["S1873994613002420"],"URL":"https:\/\/doi.org\/10.1016\/j.crohns.2013.07.004","relation":{},"ISSN":["1873-9946"],"issn-type":[{"type":"print","value":"1873-9946"}],"subject":[],"published":{"date-parts":[[2014,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients","name":"articletitle","label":"Article Title"},{"value":"Journal of Crohn's and Colitis","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.crohns.2013.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}